Jade Biosciences, Inc. Noncash or Part Noncash Acquisition, Other Liabilities Assumed
Jade Biosciences, Inc. (JBIO) reported Noncash or Part Noncash Acquisition, Other Liabilities Assumed of $1.02 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 · last filed 2026-08-10
- Jade Biosciences, Inc. noncash or part noncash acquisition, other liabilities assumed for the quarter ending 2025-12-31 was $0.00.
- Jade Biosciences, Inc. noncash or part noncash acquisition, other liabilities assumed for the quarter ending 2025-09-30 was $0.00.
- Jade Biosciences, Inc. noncash or part noncash acquisition, other liabilities assumed for fiscal 2025 was $1.02M.
| Period end | Noncash or Part Noncash Acquisition, Other Liabilities Assumed 3 month | Noncash or Part Noncash Acquisition, Other Liabilities Assumed 6 month | Noncash or Part Noncash Acquisition, Other Liabilities Assumed 9 month | Noncash or Part Noncash Acquisition, Other Liabilities Assumed 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | $1.02M 10-K · filed 2026-03-06 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.02M 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $1.02M 10-Q · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |